Anders Berkenstam,Keith Lorimer,Michael Robin Witt,Stefan Rehnmark,Stephen Watt
申请号：
BRPI0923504
公开号：
BRPI0923504A2
申请日:
2009.12.11
申请国别(地区):
BR
年份:
2020
代理人:
摘要：
The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate； crystalline genistein potassium salt dihydrate； crystalline genistein calcium salt； crystalline genistein magnesium salt； crystalline genistein L-lysine salt； crystalline genistein N-methylglucamine salt； crystalline genistein N-ethylglucamine salt； crystalline genistein diethylamine salt； and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt.
